O	0	10	Randomized
O	11	19	clinical
O	20	25	trial
O	26	28	of
O	29	39	prevention
O	40	42	of
B-condition	43	49	seroma
I-condition	50	59	formation
O	60	65	after
O	66	76	mastectomy
O	77	79	by
B-intervention	80	85	local
I-intervention	86	104	methylprednisolone
I-intervention	105	114	injection
O	114	115	.

O	116	122	Seroma
O	123	132	formation
O	132	133	,
O	134	137	the
O	138	142	most
O	143	152	prevalent
O	153	166	postoperative
O	167	179	complication
O	180	185	after
O	186	196	mastectomy
O	196	197	,
O	198	200	is
O	201	203	an
O	204	216	inflammatory
O	217	224	process
O	225	229	that
O	230	232	is
O	233	244	potentially
O	245	256	preventable
O	257	260	via
O	261	266	local
O	267	274	steroid
O	275	289	administration
O	289	290	.

O	291	295	This
O	296	301	study
O	302	314	investigated
O	315	318	the
O	319	325	effect
O	326	328	of
O	329	334	local
O	335	342	steroid
O	343	357	administration
O	358	360	on
O	361	367	seroma
O	368	377	formation
O	377	378	.

O	379	383	This
O	384	387	was
O	388	389	a
O	390	396	double
O	396	397	-
O	397	402	blind
O	403	413	randomized
O	414	421	placebo
O	421	422	-
O	422	432	controlled
O	433	445	intervention
O	446	451	study
O	452	454	of
O	455	456	a
O	457	463	single
O	464	468	dose
O	469	471	of
O	472	474	80
O	475	477	mg
O	478	496	methylprednisolone
O	497	503	versus
B-control	504	510	saline
O	511	513	on
O	514	520	seroma
O	521	530	formation
O	531	536	after
O	537	547	mastectomy
O	547	548	.

O	549	557	Patients
O	558	562	were
O	563	570	further
O	571	581	classified
O	582	591	according
O	592	594	to
O	595	598	the
O	599	607	surgical
O	608	616	axillary
O	617	626	procedure
O	626	627	:
O	628	638	mastectomy
O	639	643	with
O	644	652	sentinel
O	653	658	lymph
O	659	663	node
O	664	670	biopsy
O	671	672	(
O	672	673	M
O	674	675	+
O	676	680	SLNB
O	680	681	)
O	682	684	or
O	685	695	mastectomy
O	696	700	with
O	701	706	level
O	707	708	I
O	708	709	-
O	709	711	II
O	712	720	axillary
O	721	726	lymph
O	727	731	node
O	732	742	dissection
O	743	744	(
O	744	745	M
O	746	747	+
O	748	752	ALND
O	752	753	)
O	753	754	.

O	755	765	Treatments
O	766	770	were
O	771	783	administered
O	784	788	into
O	789	792	the
O	793	798	wound
O	799	805	cavity
O	806	809	via
O	810	813	the
O	814	819	drain
O	820	827	orifice
O	828	837	following
O	838	845	removal
O	846	848	of
O	849	852	the
O	853	858	drain
O	859	861	on
O	862	865	the
O	866	871	first
O	872	875	day
O	876	881	after
O	882	889	surgery
O	889	890	.

O	891	894	The
O	895	902	primary
O	903	911	endpoint
O	912	915	was
B-outcome-Measure	916	922	seroma
I-outcome-Measure	923	932	formation
O	932	933	;
O	934	943	secondary
O	944	953	endpoints
O	954	962	included
O	963	966	the
B-outcome-Measure	967	976	frequency
I-outcome-Measure	977	979	of
I-outcome-Measure	980	984	side
I-outcome-Measure	984	985	-
I-outcome-Measure	985	992	effects
I-outcome-Measure	993	996	and
I-outcome-Measure	997	1010	complications
O	1010	1011	.

O	1012	1013	A
O	1014	1019	total
O	1020	1022	of
B-total-participants	1023	1026	212
B-eligibility	1027	1032	women
I-eligibility	1033	1042	scheduled
I-eligibility	1043	1046	for
I-eligibility	1047	1057	mastectomy
I-eligibility	1058	1061	for
I-eligibility	1062	1069	primary
I-eligibility	1070	1076	breast
I-eligibility	1077	1083	cancer
O	1084	1088	were
O	1089	1097	included
O	1097	1098	.

B-outcome	1099	1104	After
I-outcome	1105	1106	M
I-outcome	1107	1108	+
I-outcome	1109	1113	SLNB
O	1113	1114	,
B-iv-bin-abs	1115	1117	32
O	1118	1119	(
B-iv-bin-percent	1119	1121	46
I-iv-bin-percent	1122	1125	per
I-iv-bin-percent	1126	1130	cent
O	1130	1131	)
O	1132	1134	of
B-intervention-participants	1135	1137	69
O	1138	1143	women
B-outcome	1144	1153	developed
I-outcome	1154	1155	a
I-outcome	1156	1162	seroma
O	1163	1165	in
O	1166	1169	the
O	1170	1188	methylprednisolone
O	1189	1194	group
O	1194	1195	,
O	1196	1204	compared
O	1205	1209	with
B-cv-bin-abs	1210	1212	52
O	1213	1214	(
B-cv-bin-percent	1214	1216	78
I-cv-bin-percent	1217	1220	per
I-cv-bin-percent	1221	1225	cent
O	1225	1226	)
O	1227	1229	of
B-control-participants	1230	1232	67
O	1233	1235	in
O	1236	1239	the
O	1240	1246	saline
O	1247	1252	group
O	1253	1254	(
O	1254	1255	P
O	1256	1257	<
O	1258	1259	0
O	1259	1260	.
O	1260	1263	001
O	1263	1264	)
O	1264	1265	.

O	1266	1269	The
B-outcome	1270	1274	mean
I-outcome	1275	1285	cumulative
I-outcome	1286	1292	seroma
I-outcome	1293	1299	volume
O	1300	1302	in
O	1303	1306	the
O	1307	1316	intention
O	1316	1317	-
O	1317	1319	to
O	1319	1320	-
O	1320	1325	treat
O	1326	1336	population
O	1337	1340	for
O	1341	1344	the
O	1345	1350	first
B-outcome	1351	1353	10
I-outcome	1354	1357	and
I-outcome	1358	1360	30
I-outcome	1361	1365	days
O	1366	1369	was
O	1370	1383	significantly
O	1384	1389	lower
O	1390	1392	in
O	1393	1396	the
O	1397	1415	methylprednisolone
O	1416	1421	group
O	1422	1423	(
B-iv-cont-mean	1423	1425	24
I-iv-cont-mean	1426	1428	ml
O	1429	1435	versus
B-cv-cont-mean	1436	1439	127
I-cv-cont-mean	1440	1442	ml
O	1443	1445	in
O	1446	1449	the
O	1450	1456	saline
O	1457	1462	group
O	1462	1463	,
O	1464	1467	and
B-iv-cont-mean	1468	1471	177
O	1472	1478	versus
B-cv-cont-mean	1479	1482	328
I-cv-cont-mean	1483	1485	ml
O	1486	1498	respectively
O	1498	1499	)
O	1500	1501	(
O	1501	1502	P
O	1503	1504	<
O	1505	1506	0
O	1506	1507	.
O	1507	1510	001
O	1510	1511	)
O	1511	1512	.

O	1513	1518	After
O	1519	1520	M
O	1521	1522	+
O	1523	1527	ALND
O	1527	1528	,
O	1529	1536	similar
O	1537	1548	proportions
O	1549	1551	of
O	1552	1560	patients
O	1561	1570	developed
O	1571	1572	a
B-outcome	1573	1579	seroma
O	1580	1582	in
O	1583	1586	the
O	1587	1605	methylprednisolone
O	1606	1607	(
B-iv-bin-abs	1607	1609	35
O	1610	1612	of
B-intervention-participants	1613	1615	37
O	1615	1616	,
B-iv-bin-percent	1617	1619	95
I-iv-bin-percent	1620	1623	per
I-iv-bin-percent	1624	1628	cent
O	1628	1629	)
O	1630	1633	and
O	1634	1640	saline
O	1641	1642	(
B-cv-bin-abs	1642	1644	34
O	1645	1647	of
B-control-participants	1648	1650	36
O	1650	1651	,
B-cv-bin-percent	1652	1654	94
I-cv-bin-percent	1655	1658	per
I-cv-bin-percent	1659	1663	cent
O	1663	1664	)
O	1665	1671	groups
O	1671	1672	,
O	1673	1676	and
O	1677	1695	methylprednisolone
O	1696	1710	administration
O	1711	1714	had
O	1715	1717	no
O	1718	1729	significant
O	1730	1736	effect
O	1737	1739	on
O	1740	1746	seroma
O	1747	1756	formation
O	1756	1757	.

O	1758	1760	No
O	1761	1772	differences
O	1773	1775	in
B-outcome	1776	1785	infection
I-outcome	1786	1790	rate
O	1791	1795	were
O	1796	1804	observed
O	1804	1805	.

O	1806	1824	Methylprednisolone
O	1825	1837	administered
O	1838	1842	into
O	1843	1846	the
O	1847	1852	wound
O	1853	1859	cavity
O	1860	1862	on
O	1863	1866	the
O	1867	1872	first
O	1873	1876	day
O	1877	1882	after
O	1883	1884	M
O	1885	1886	+
O	1887	1891	SLNB
O	1892	1899	exerted
O	1900	1901	a
O	1902	1908	highly
O	1909	1920	significant
O	1921	1931	preventive
O	1932	1938	effect
O	1939	1946	against
O	1947	1953	seroma
O	1954	1963	formation
O	1964	1970	during
O	1971	1974	the
O	1975	1979	next
O	1980	1982	30
O	1983	1987	days
O	1987	1988	.

O	1989	1993	This
O	1994	2000	effect
O	2001	2004	was
O	2005	2008	not
O	2009	2013	seen
O	2014	2016	in
O	2017	2020	the
O	2021	2022	M
O	2023	2024	+
O	2025	2029	ALND
O	2030	2035	group
O	2035	2036	.

O	2037	2043	Future
O	2044	2051	studies
O	2052	2055	may
O	2056	2063	clarify
O	2064	2071	whether
O	2072	2078	higher
O	2079	2081	or
O	2082	2090	repeated
O	2091	2109	methylprednisolone
O	2110	2115	doses
O	2116	2124	increase
O	2125	2128	the
O	2129	2137	efficacy
O	2137	2138	.
